EA200100524A1 - Амиды антраниловой кислоты и их применение в качестве лекарственных средств - Google Patents
Амиды антраниловой кислоты и их применение в качестве лекарственных средствInfo
- Publication number
- EA200100524A1 EA200100524A1 EA200100524A EA200100524A EA200100524A1 EA 200100524 A1 EA200100524 A1 EA 200100524A1 EA 200100524 A EA200100524 A EA 200100524A EA 200100524 A EA200100524 A EA 200100524A EA 200100524 A1 EA200100524 A1 EA 200100524A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- medicines
- amides
- application
- antranilic acid
- antranilic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
В заявке описываются амиды антраниловой кислоты и их применение в качестве лекарственных средств для лечения заболеваний, обусловленных персистирующим ангиогенезом, а также промежуточные продукты для получения этих амидов антраниловой кислоты.Отчет о международном поиске был опубликован 2000.08.17.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9824579.8A GB9824579D0 (en) | 1998-11-10 | 1998-11-10 | Organic compounds |
DE1999110396 DE19910396C2 (de) | 1999-03-03 | 1999-03-03 | Anthranilsäureamide und deren Verwendung als Arzneimittel |
PCT/EP1999/008478 WO2000027819A2 (de) | 1998-11-10 | 1999-11-09 | Anthranilsäureamide und deren verwendung als arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200100524A1 true EA200100524A1 (ru) | 2002-02-28 |
EA004701B1 EA004701B1 (ru) | 2004-06-24 |
Family
ID=26052266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200100524A EA004701B1 (ru) | 1998-11-10 | 1999-11-09 | Амиды антраниловой кислоты и их применение в качестве лекарственных средств |
Country Status (23)
Country | Link |
---|---|
US (1) | US7122547B1 (ru) |
EP (1) | EP1129074A2 (ru) |
JP (1) | JP2002529452A (ru) |
KR (2) | KR100855396B1 (ru) |
CN (1) | CN1151133C (ru) |
AU (1) | AU771180B2 (ru) |
BG (1) | BG65371B1 (ru) |
BR (1) | BR9915553A (ru) |
CA (1) | CA2350208A1 (ru) |
CZ (1) | CZ20011631A3 (ru) |
EA (1) | EA004701B1 (ru) |
EE (1) | EE200100258A (ru) |
HK (1) | HK1041882A1 (ru) |
HR (1) | HRP20010402A2 (ru) |
HU (1) | HUP0104425A3 (ru) |
NO (1) | NO320647B1 (ru) |
NZ (1) | NZ511413A (ru) |
PL (1) | PL348349A1 (ru) |
SK (1) | SK6072001A3 (ru) |
TR (1) | TR200101307T2 (ru) |
UA (1) | UA71587C2 (ru) |
WO (1) | WO2000027819A2 (ru) |
YU (1) | YU31801A (ru) |
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6635657B1 (en) * | 1998-12-23 | 2003-10-21 | Eli Lilly And Company | Aromatic amides |
DE10023485A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel |
DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
CN1234358C (zh) | 2000-06-21 | 2006-01-04 | 弗·哈夫曼-拉罗切有限公司 | 苯并噻唑衍生物 |
HUP0400708A3 (en) * | 2000-12-07 | 2007-10-29 | Cv Therapeutics | Substituted 1,3,5-triazine and pyrimidine derivatives, their use and pharmaceutical compositions containing them |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
EP3351246B8 (en) | 2001-02-19 | 2019-09-18 | Novartis Pharma AG | Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis |
US6864255B2 (en) | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
DE10123587B4 (de) * | 2001-05-08 | 2005-04-07 | Schering Ag | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel |
DE10123573B4 (de) * | 2001-05-08 | 2005-06-02 | Schering Ag | N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel |
BR0209485A (pt) * | 2001-05-08 | 2004-07-06 | Schering Ag | Antranilamidapiridinamidas seletivas como inibidores vegfr-2 e vegfr-3 |
WO2003000678A1 (de) * | 2001-05-08 | 2003-01-03 | Schering Aktiengesellschaft | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel |
EP1389201A1 (de) | 2001-05-08 | 2004-02-18 | Schering Aktiengesellschaft | N-oxidanthranylamid-derivate und deren verwendung als arzneimittel |
IL158274A0 (en) | 2001-05-16 | 2004-05-12 | Novartis Ag | Combination comprising n-{5-[4-(4-methyl-piperazino-methyl) benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and chemotherapeutic agent |
JPWO2002100833A1 (ja) * | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Rhoキナーゼ阻害剤 |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
WO2003030902A1 (en) | 2001-10-09 | 2003-04-17 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
GB0126902D0 (en) * | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
BR0311173A (pt) | 2002-05-16 | 2005-03-15 | Novartis Ag | Uso de agentes de ligação do receptor de edg em câncer |
US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7094789B2 (en) | 2002-07-22 | 2006-08-22 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivatives |
DE10235690A1 (de) * | 2002-07-31 | 2004-02-19 | Schering Ag | VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
DE60329030D1 (de) | 2002-12-04 | 2009-10-08 | Ore Pharmaceuticals Inc | Melanocortin-rezeptormodulatoren |
TWI299664B (en) | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
US7087761B2 (en) | 2003-01-07 | 2006-08-08 | Hoffmann-La Roche Inc. | Cyclization process for substituted benzothiazole derivatives |
EP1603883B1 (en) * | 2003-02-03 | 2012-03-28 | Janssen Pharmaceutica NV | Quinoline-derived amide modulators of vanilloid vr1 receptor |
ATE450533T1 (de) * | 2003-02-14 | 2009-12-15 | Glaxo Group Ltd | Carboxamidderivate |
ES2441176T3 (es) | 2003-03-07 | 2014-02-03 | Santen Pharmaceutical Co., Ltd. | Nuevo compuesto que tiene un grupo 4-piridilalquiltio como sustituyente |
TW200505442A (en) | 2003-05-19 | 2005-02-16 | Genomics Inst Of The Novartis Res Foundation | Immunosuppressant compounds and compositions |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
JP2006526660A (ja) * | 2003-06-05 | 2006-11-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Vr1レセプターのモジュレーター |
DE10327719A1 (de) * | 2003-06-13 | 2005-01-20 | Schering Ag | VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone |
US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
EP1653951B1 (en) * | 2003-07-11 | 2011-12-28 | Merck Patent GmbH | Benzimidazole derivatives as raf kinase inhibitors |
GB0326601D0 (en) * | 2003-11-14 | 2003-12-17 | Novartis Ag | Organic compounds |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
DK1717229T3 (da) | 2004-02-17 | 2011-09-19 | Santen Pharmaceutical Co Ltd | Ny cyklisk forbindelse med 4-pyridylalkylthiogruppe med deri indført (u)substitueret amino |
DE102004009238A1 (de) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
DE102004011720B4 (de) * | 2004-03-10 | 2008-04-03 | Bayer Schering Pharma Aktiengesellschaft | Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie |
US7427390B2 (en) * | 2004-03-10 | 2008-09-23 | Schering Ag | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy |
DK1753760T3 (da) | 2004-05-24 | 2008-04-14 | Hoffmann La Roche | 4-hydroxy-4-methyl-piperidin-1-carboxylsyre-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amid |
DE102004039876A1 (de) * | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
NZ553646A (en) | 2004-09-22 | 2010-07-30 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between MDM2 and p53 |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
CA2586931C (en) | 2004-11-05 | 2013-08-06 | Paul Spurr | Process for preparation of isonicotinic acid derivatives |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
WO2006093253A1 (ja) * | 2005-03-03 | 2006-09-08 | Santen Pharmaceutical Co., Ltd. | キノリルアルキルチオ基を有する新規環式化合物 |
PT1863818E (pt) | 2005-03-23 | 2010-04-09 | Hoffmann La Roche | Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2 |
EP1864977B1 (en) | 2005-03-31 | 2015-07-29 | Santen Pharmaceutical Co., Ltd. | Novel cyclic compound having pyrimidinylalkylthio group |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
KR101121292B1 (ko) | 2005-09-27 | 2012-04-13 | 에프. 호프만-라 로슈 아게 | Mglur2 길항제로서 옥사다이아졸일 피라졸로-피리미딘 |
WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
CA2933875C (en) | 2005-11-21 | 2018-06-26 | Novartis Ag | 40-o-(2-hydroxyethyl)-rapamycin for use as a sole drug substance in the treatment of carcinoid tumors arising from the foregut, midgut, or hindgut |
KR20080071562A (ko) * | 2005-11-30 | 2008-08-04 | 아스텔라스세이야쿠 가부시키가이샤 | 2-아미노벤즈아미드 유도체 |
US8232298B2 (en) | 2006-03-22 | 2012-07-31 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between MDM2 and P53 |
ATE470665T1 (de) | 2006-03-22 | 2010-06-15 | Janssen Pharmaceutica Nv | Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 |
AU2007240548A1 (en) | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
RU2469721C2 (ru) | 2006-05-09 | 2012-12-20 | Новартис Аг | Комбинация, включающая комплексон железа и противоопухолевый агент, и ее применение |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
CN101516885A (zh) | 2006-09-29 | 2009-08-26 | 诺瓦提斯公司 | 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物 |
WO2008077809A1 (en) * | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Process for the manufacture of 7-oxa-bicyclo derivatives |
JP5216341B2 (ja) | 2007-01-29 | 2013-06-19 | 参天製薬株式会社 | 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体 |
AU2008216327A1 (en) | 2007-02-15 | 2008-08-21 | Novartis Ag | Combination of LBH589 with other therapeutic agents for treating cancer |
EP1975166A1 (en) * | 2007-03-30 | 2008-10-01 | Bayer Schering Pharma AG | Synthesis of anthranilamides |
ES2534899T3 (es) | 2007-08-06 | 2015-04-30 | Janssen Pharmaceutica, N.V. | Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53 |
AU2009228778B2 (en) | 2008-03-26 | 2012-04-19 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases B |
AU2009287152B2 (en) | 2008-08-27 | 2014-09-25 | Leo Pharma A/S | Pyridine derivatives as VEGFR-2 receptor and protein tyrosine kinase inhibitors |
WO2010043050A1 (en) | 2008-10-16 | 2010-04-22 | Celator Pharmaceuticals Corporation | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
ES2478842T3 (es) | 2008-12-18 | 2014-07-23 | Novartis Ag | Sal clorhidrato del ácido 1-(4-(1-((E)-4-ciclohexil-3-trifluorometil-benziloxiimino)-etil)-2-etil-benzil)-azetidina-3-carboxílico |
BRPI0922457A2 (pt) | 2008-12-18 | 2015-12-15 | Novartis Ag | forma polimórfica de ácido 1-(4-{1-[(e)-4-ciclo-hexil-3-trifluormetil-benziloxi-imino]-etil)-2-etil-benzil)-azetidino-3-carboxílico" |
RU2518114C3 (ru) | 2008-12-18 | 2021-11-24 | Новартис Аг | Гемифумаратная соль 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил] азетидин-3-карбоновой кислоты |
US20110281917A1 (en) | 2009-01-29 | 2011-11-17 | Darrin Stuart | Substituted Benzimidazoles for the Treatment of Astrocytomas |
JP5612611B2 (ja) | 2009-02-04 | 2014-10-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | 抗癌剤としてのインドール誘導体 |
SG176105A1 (en) | 2009-06-26 | 2011-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
BR112012003262A8 (pt) | 2009-08-12 | 2016-05-17 | Novartis Ag | compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação |
EP2467141B1 (en) | 2009-08-17 | 2018-10-31 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
WO2011020861A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
CN102574785A (zh) | 2009-08-26 | 2012-07-11 | 诺瓦提斯公司 | 四取代的杂芳基化合物和它们作为mdm2和/或mdm4调节剂的用途 |
CA2773661A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
PE20121471A1 (es) | 2009-11-04 | 2012-11-01 | Novartis Ag | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek |
US20120289501A1 (en) | 2009-11-25 | 2012-11-15 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
ES2484171T3 (es) | 2009-12-08 | 2014-08-11 | Novartis Ag | Derivados de sulfonamidas heterocíclicas |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
EP2582680A1 (en) | 2010-06-17 | 2013-04-24 | Novartis AG | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
EP2582681A1 (en) | 2010-06-17 | 2013-04-24 | Novartis AG | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2011160206A1 (en) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarkers for non-hodgkin lymphomas and uses thereof |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
DK2614369T3 (en) | 2010-09-10 | 2016-05-02 | Epizyme Inc | METHOD FOR DETERMINING THE SUITABILITY OF HUMAN EZH2 INHIBITORS TREATED |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
US20130338152A1 (en) | 2011-03-08 | 2013-12-19 | Irm Llc | Fluorophenyl bicyclic heteroaryl compounds |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
EA201391820A1 (ru) | 2011-06-09 | 2014-12-30 | Новартис Аг | Гетероциклические сульфонамидные производные |
WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
EP2721007B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Cyclohexyl isoquinolinone compounds |
EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
EP2785717B1 (en) | 2011-11-29 | 2016-01-13 | Novartis AG | Pyrazolopyrrolidine compounds |
US20140357666A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
AU2012355613A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
WO2013096060A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
EA201491259A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания |
WO2013096059A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
CN102603729A (zh) * | 2012-01-12 | 2012-07-25 | 贵州大学 | N-(2-(取代苯并噻唑-2-氨基甲酰基)-取代苯基)吡啶甲酰胺类衍生物 |
JO3357B1 (ar) | 2012-01-26 | 2019-03-13 | Novartis Ag | مركبات إيميدازوبيروليدينون |
US9725427B2 (en) | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
CN104245701A (zh) | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
PT3628670T (pt) | 2012-04-13 | 2022-12-02 | Epizyme Inc | Forma salina de um inibidor de ezh2 |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
RU2658919C2 (ru) | 2012-10-15 | 2018-06-26 | Эпизайм, Инк. | Замещенные бензольные соединения |
EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
CN103130696B (zh) * | 2013-03-21 | 2014-06-11 | 山东大学 | 邻氨基苯甲酰胺类化合物及其制备方法与应用 |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
CN103405434A (zh) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | Vegfr-2抑制剂及其用途 |
PT3057962T (pt) | 2013-10-16 | 2023-11-07 | Epizyme Inc | Forma de sal cloridrato para inibição de ezh2 |
CN104163794A (zh) * | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
RU2695230C2 (ru) | 2014-07-31 | 2019-07-22 | Новартис Аг | Сочетанная терапия |
WO2019077037A1 (en) | 2017-10-18 | 2019-04-25 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | METHODS AND COMPOUNDS FOR ENHANCED IMMUNE CELL THERAPY |
EP3730483B1 (en) | 2017-12-21 | 2023-08-30 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | Class of pyrimidine derivative kinase inhibitors |
EP4058465A1 (en) | 2019-11-14 | 2022-09-21 | Cohbar Inc. | Cxcr4 antagonist peptides |
US11091447B2 (en) | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
CN117479935A (zh) * | 2021-04-19 | 2024-01-30 | 上海药苑生物科技有限公司 | 用于治疗川崎病的苯并噻唑和喹啉衍生物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3226394A (en) * | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
US3409668A (en) * | 1964-11-07 | 1968-11-05 | Palazzo Giuseppe | Substituted anthranilamides and process for the preparation thereof |
JPS5744672B2 (ru) * | 1974-05-24 | 1982-09-22 | ||
DE2652144A1 (de) | 1976-11-16 | 1978-05-18 | Merck Patent Gmbh | Neue chinazolindione |
EP0117462A3 (en) * | 1983-02-28 | 1986-08-20 | American Cyanamid Company | N-(2-4-(1h-imidazol-1-yl)alkyl)arylamides |
US4568687A (en) | 1983-02-28 | 1986-02-04 | American Cyanamid Company | N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions |
FR2689508B1 (fr) | 1992-04-01 | 1994-06-17 | Fournier Ind & Sante | Derives de l'imidazole, leur procede de preparation et leur application en therapeutique. |
HUT74450A (en) * | 1993-12-27 | 1996-12-30 | Eisai Co Ltd | Anthranilic acid derivative and pharmaceutical compns. contg. such compds. |
DK0888353T3 (da) * | 1996-03-15 | 2003-10-27 | Novartis Ag | N-7-Heterocyclyl-pyrrolo[2,3-d]pyrimidiner og deres anvendelse |
-
1999
- 1999-09-11 UA UA2001063917A patent/UA71587C2/ru unknown
- 1999-11-09 KR KR1020077015852A patent/KR100855396B1/ko not_active IP Right Cessation
- 1999-11-09 US US09/831,506 patent/US7122547B1/en not_active Expired - Fee Related
- 1999-11-09 YU YU31801A patent/YU31801A/sh unknown
- 1999-11-09 PL PL99348349A patent/PL348349A1/xx not_active Application Discontinuation
- 1999-11-09 CZ CZ20011631A patent/CZ20011631A3/cs unknown
- 1999-11-09 KR KR1020017005800A patent/KR100777476B1/ko not_active IP Right Cessation
- 1999-11-09 HU HU0104425A patent/HUP0104425A3/hu unknown
- 1999-11-09 JP JP2000580999A patent/JP2002529452A/ja not_active Withdrawn
- 1999-11-09 SK SK607-2001A patent/SK6072001A3/sk unknown
- 1999-11-09 CN CNB998130788A patent/CN1151133C/zh not_active Expired - Fee Related
- 1999-11-09 WO PCT/EP1999/008478 patent/WO2000027819A2/de not_active Application Discontinuation
- 1999-11-09 NZ NZ511413A patent/NZ511413A/en unknown
- 1999-11-09 TR TR2001/01307T patent/TR200101307T2/xx unknown
- 1999-11-09 EE EEP200100258A patent/EE200100258A/xx unknown
- 1999-11-09 EA EA200100524A patent/EA004701B1/ru not_active IP Right Cessation
- 1999-11-09 CA CA002350208A patent/CA2350208A1/en not_active Abandoned
- 1999-11-09 AU AU10454/00A patent/AU771180B2/en not_active Ceased
- 1999-11-09 BR BR9915553-2A patent/BR9915553A/pt not_active Application Discontinuation
- 1999-11-09 EP EP99953967A patent/EP1129074A2/de not_active Withdrawn
-
2001
- 2001-05-07 NO NO20012245A patent/NO320647B1/no unknown
- 2001-05-25 HR HR20010402A patent/HRP20010402A2/hr not_active Application Discontinuation
- 2001-06-11 BG BG105588A patent/BG65371B1/bg unknown
-
2002
- 2002-05-14 HK HK02103628A patent/HK1041882A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU771180B2 (en) | 2004-03-18 |
TR200101307T2 (tr) | 2002-05-21 |
KR100855396B1 (ko) | 2008-08-29 |
PL348349A1 (en) | 2002-05-20 |
KR20070087027A (ko) | 2007-08-27 |
EA004701B1 (ru) | 2004-06-24 |
EE200100258A (et) | 2002-12-16 |
UA71587C2 (ru) | 2004-12-15 |
SK6072001A3 (en) | 2002-01-07 |
NO20012245L (no) | 2001-07-10 |
HUP0104425A3 (en) | 2003-05-28 |
NZ511413A (en) | 2004-01-30 |
CN1151133C (zh) | 2004-05-26 |
WO2000027819A2 (de) | 2000-05-18 |
JP2002529452A (ja) | 2002-09-10 |
CZ20011631A3 (cs) | 2001-10-17 |
EP1129074A2 (de) | 2001-09-05 |
WO2000027819A3 (de) | 2000-08-17 |
NO20012245D0 (no) | 2001-05-07 |
HRP20010402A2 (en) | 2003-10-31 |
HK1041882A1 (en) | 2002-07-26 |
YU31801A (sh) | 2003-12-31 |
KR100777476B1 (ko) | 2007-11-16 |
BR9915553A (pt) | 2001-08-14 |
KR20010075689A (ko) | 2001-08-09 |
CA2350208A1 (en) | 2000-05-18 |
BG65371B1 (bg) | 2008-04-30 |
NO320647B1 (no) | 2006-01-09 |
US7122547B1 (en) | 2006-10-17 |
BG105588A (en) | 2002-04-30 |
AU1045400A (en) | 2000-05-29 |
CN1325384A (zh) | 2001-12-05 |
HUP0104425A2 (hu) | 2002-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200100524A1 (ru) | Амиды антраниловой кислоты и их применение в качестве лекарственных средств | |
EA200000759A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
MA26901A1 (fr) | Nouvelle composition pharmaceutique | |
EA199901031A1 (ru) | Производные бензимидазола | |
MX9604378A (es) | Amidas de acido quinolin-2-carboxilico sustituidas, su preparacion y su empleo como medicamentos, asi como productos intermedios. | |
EA200001223A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
EA200001224A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
HUT76511A (en) | Benzoyl derivatives, preparation and use thereot | |
FI20115753A (fi) | Farmaseuttisia koostumuksia IL-6:n tuoton aiheuttamien sairauksien hoitoon | |
EA200300293A1 (ru) | Противовоспалительные конденсированные пирролокарбазолы | |
EA199900494A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
EA200300776A1 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
EE04938B1 (et) | Orto-asendatud antraniilhappeamiidid ja nende kasutamine ravimitena | |
EA200100127A1 (ru) | Производные фенилксантина | |
EA200201214A1 (ru) | Замещенные тиоацетамиды | |
EA200000741A1 (ru) | Новые производные дигидроксигексановой кислоты | |
TR200100637T2 (tr) | Yeni doğal ürün türevleri | |
EA200000242A1 (ru) | Применение фанхинона для лечения болезни альцгеймера | |
ITMI922742A0 (it) | Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. | |
MY103593A (en) | Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation | |
DE689838T1 (de) | Verwendung von Diademosim 5',5'''-p1,p4-Tetraphosphat zur Behandlung von ischämischen Myokard-Erkrankungen | |
DK0538690T3 (da) | Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler | |
DE50000562D1 (de) | Mittel zur behandlung von pigmentierungsstörungen | |
DOP2001000245A (es) | Amidas de acido fenilciclohexanocarboxilico sustituido y su uso. | |
DE500713T1 (de) | Derivate des 3,3,5-trimethylcyclohexylesters von 2-methylpropionsaeure, ihr herstellungsverfahren sowie diese enthaltende therapeutische kompositionen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |